Niagen Bioscience’s Clinical Expansion and Strong Financial Performance Drive Buy Rating

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on NAGE stock, giving a Buy rating today.

Ram Selvaraju has given his Buy rating due to a combination of factors, primarily the expansion of Niagen Bioscience’s clinical footprint and the superior performance of its Niagen IV product. The company has successfully increased its presence in the U.S. market by adding new clinics that offer its pharmaceutical-grade Niagen IV and injections, which are known for boosting NAD+ levels more effectively than competing products. This expansion is expected to drive rapid market uptake, further solidifying Niagen’s position in the industry.
Additionally, Niagen Bioscience has demonstrated strong financial performance, exceeding revenue expectations in the first quarter of 2025 with $30.5 million in top-line revenue, surpassing the forecasted $27 million. The company projects a robust year-over-year revenue growth of 20-25%, which has led to an upward revision of revenue estimates for both 2025 and 2026. These financial achievements, coupled with the product’s competitive advantages, underpin Selvaraju’s positive outlook and the reiterated Buy rating with a 12-month price target of $11.

In another report released today, Roth MKM also reiterated a Buy rating on the stock with a $10.00 price target.